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Abstract: Asthma poses a significant burden on patients, families,
health care providers, and the medical system. While efforts to stan-
dardize care through guidelines have expanded, difficulty in managing
severe asthma has encouraged research about its pathobiology and
treatment options. Novel biologic therapeutics are being developed for
the treatment of asthma and are of potential use for severe refractory
asthma, especially where the increased cost of such agents is more
likely justified. This review will summarize currently approved (oma-
lizumab) and investigational biologic agents for asthma, such as anti-
bodies, soluble receptors, and other protein-based antagonists, and
highlight recent published data on efficacy and safety of these therapies
in humans. As these newer agents with highly targeted pharmacology
are tested in asthma, we are also poised to learn more about the role of
cytokines and other molecules in the pathophysiology of asthma.
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INTRODUCTION
There is an increasing sense of urgency in addressing theproblems of morbidity and mortality caused by asthma.
Despite the well-known and fairly consistent efficacy of
drugs such as inhaled corticosteroids, leukotriene modifiers
and 2 agonists for the majority of asthmatics, as many as
10% suffer from severe disease inadequately controlled by
conventional therapy. Severe and sustained symptoms lead to
poor quality of life, disproportionate use of health care
resources, and significant adverse effects from hospitaliza-
tions and frequent need for systemic steroids. Current asthma
guidelines offer inadequate assistance in the management of
severe refractory asthmatic patients, in part because of a
paucity of other treatment options. Novel biologic therapeu-
tics are being developed for the treatment of asthma and are
of potential use for severe refractory asthma, especially
where the increased cost of such agents is more likely
justified. This review will briefly summarize what is meant by
“biologic therapies” and then highlight recent published data
on efficacy and safety of these therapies for asthma.
WHAT ARE BIOLOGIC THERAPIES?
Biologic therapies have revolutionized the treatment of
many diseases including asthma. By definition, the term
“biologics” or “biologicals” include a variety of protein-
based therapeutics, such as antibodies, soluble receptors (eg,
etanercept), recombinant protein-based receptor antagonists
(eg, pitrakinra) and other related structures. Their main ad-
vantages include the duration of action and highly specific
and strong binding to the target of interest; their main disad-
vantages are the cost and need for parenteral administration.
Most biologicals in clinical use are antibodies, and their
generic names contain standard nomenclature as a suffix to
indicate their origins (Fig. 1). Initially, pure murine antibod-
ies were created with hybridoma technology, generating ther-
apies that were 100% mouse with generic names given the
suffix “momab” (eg, ibritumomab); however, immunogenic-
ity of mouse antibodies in human subjects caused reduced
efficacy and increased risk of infusion reactions including
anaphylaxis and death. To reduce immunogenicity, chimeric anti-
bodies (“ximabs” like rituximab)were engineered. These antibodies
are a marriage of murine variable regions combined with human
constant regions, creating antibodies that are 80% human.
These were a step forward but still had the potential for being
immunogenic. Humanized monoclonal antibodies (“zumabs”
such as omalizumab) go one step further, where now only the
hypervariable regions of the mouse antibody are retained,
while the remaining 95% of the antibody is molecularly
replaced by human sequences. In the latest approach, fully
human antibodies (“umabs” such as adalimumab) can be
created by using phage display technology and molecular
biology or more directly by immunizing mice that have had
their immunoglobulin genes replaced with human versions.1
Newer artificial antibody structures (Fig. 2) such as bispecific
antibodies, mix 2 separate arms with 2 different binding
specificities to target 2 different types of antigens [eg, a single
antibody where one arm binds interleukin (IL)-4 and the other
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FIGURE 1. In general, FDA-approved mAbs have emerged between 10 and 12 years after the date that the new technolo-
gies on which they were based were reported in the scientific literature. Reprinted by permission from reference 1.
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arm binds IL-13]. None of these newer antibody structures have
been tried in asthma, so the remainder of this review will focus
on available data with standard biologicals (see Table 1).
IL-4
IL-4 is important to the development of allergic inflam-
mation. It induces the IgE isotype switch and up-regulates
expression of vascular cell adhesion molecule-1 on endothe-
lium and a variety of TH2 chemokines, thus promoting
recruitment of T lymphocytes, monocytes, basophils, and
eosinophils to sites of allergic inflammation. Furthermore,
IL-4 induces mucin production and promotes the differenti-
ation of naive TH0 lymphocytes into TH2 lymphocytes that
secrete IL-4, IL-5, IL-9, and IL-13.2,3
A clinical trial studied the soluble recombinant human
IL-4 receptor (IL-4R), Nuvance in asthma. Nuvance inhibited
a decline in FEV1 during inhaled corticosteroid withdrawal
and was overall well tolerated.2,3 However, in subsequent
clinical trials in patients taking only beta agonist, soluble
IL-4R failed to demonstrate significant clinical efficacy. In
addition, Steinke et al found no clinical benefit with soluble
IL-4R as inhaled corticosteroids were tapered.4
FIGURE 2. Standard nomenclature for mAbs identifies their source with the last 4 or 5 letters: -omab, murine: -ximab, chi-
meric: -zumab, humanized: and –umab, human. The middle part of the name reflects the disease indication for which the
mAb was initially intended: -lim for immune and inflammatory diseases, -cir for cardiovascular disorders, and -tu for tumors or
neoplastic conditions. The first 3 or 4 letters may be chosen by the sponsor. Modified (by adding the structure of a bispecific
antibody) from reference 28, with permission.
TABLE 1. Examples and Characteristics of Biologic Agents Potentially Relevant to Asthma and Allergic Diseases
Target Biologic Agent Manufacturer Composition Reference
Cell surface
CD4 Keliximab SmithKline Beecham Pharmaceuticals Chimeric IgG1 monoclonal antibody 9,10
CD23 IDEC-152 Biogen IDEC Chimeric IgG1 monoclonal antibody 11
CD25 Daclizumab Roche Humanized IgG1 monoclonal antibody 12
IL-4R Pitrakinra Aerovance 15 kDa recombinant human IL-4 variant that is an
antagonist of both IL-4 and IL-13 receptor binding
21
AMG 317 Amgen Fully human IgG2 monoclonal antibody 22
IL-5R MEDI-563 MedImmune Humanized IgG1 monoclonal antibody with enhanced
antibody-dependent cellular cytotoxicity function
32
Soluble
IgE Omalizumab Genentech and Novartis Humanized IgG1 monoclonal antibody 14
IL-4 Nuvance Immunex Soluble IL-4 receptor 3
IL-4 Pascolizumab GlaxoSmithKline and Protein Design Labs Humanized IgG1 monoclonal antibody 5
IL-5 Mepolizumab GlaxoSmithKline Humanized IgG1 monoclonal antibody 23
IL-9 MEDI-528 MedImmune Humanized IgG1 monoclonal antibody 27
TNF Golimumab Centocor/Schering-Plough Fully human IgG1 monoclonal antibody 8
Infliximab Centocor Ortho Biotech Chimeric IgG1 monoclonal antibody 7
Etanercept Immunex/Amgen IgG1 fusion protein containing the extracellular
domain of the p75 TNF receptor
6
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A phase I randomized double blind placebo controlled
study evaluated the effects of pascolizumab, a humanized
anti-IL-4 antibody, in 24 patients with mild to moderate
asthma. Pascolizumab was well tolerated and no serious
adverse events occurred.5 However, a phase IIa clinical trial
in steroid-naive, mild to moderate asthmatics, did not dem-
onstrate clinical efficacy. Because the IL-4 targeting studies
have failed to demonstrate clinical efficacy, one can justify
concluding that either IL-4 is not a disease-perpetuating
cytokine in asthma, or perhaps that IL-4 was not adequately
neutralized for a sufficient amount of time, or in the right
patient population, or at the relevant site of IL-4 action. While
the former seems most likely, without convincing evidence
documenting the latter issues, the exact reason for the failure
of these studies remains speculative.
TNF
Tumor necrosis factor (TNF) is a multifunctional
proinflammatory cytokine produced by inflammatory cells
including monocytes, macrophages, mast cells, smooth mus-
cle cells, and epithelial cells. TNF may initiate airway inflam-
mation by up-regulating adhesion molecules, mucin hypersecre-
tion, and airway remodeling, and by synergizing with TH2
cytokines. Berry et al demonstrated that severe refractory asth-
matics have evidence of up-regulation of TNF as compared
with healthy controls and mild asthmatics.6
Entanercept was evaluated in a small, randomized,
double-blind placebo-controlled crossover study in 10 pa-
tients with severe refractory asthma and elevated TNF
levels, 10 patients with mild to moderate asthma, and 10
control patients. Entanercept treatment was associated with
improved FEV1, asthma related quality of life, and the
concentration of methacholine needed to provoke a 20%
decrease in FEV1. No serious adverse reactions were noted.6
In another double-blind, placebo-controlled, parallel-
group study, 38 patients with moderate asthma on inhaled
corticosteroids were treated with infliximab. Although inflix-
imab treatment did not improve the primary end point of
morning peak expiratory flow, it decreased diurnal variation
of the peak expiratory flow rate and asthma exacerbations. No
serious adverse events were noted.7
Golimumab was recently evaluated in the largest ran-
domized, double-blind, placebo-controlled study in 309 pa-
tients with severe, uncontrolled asthma. No significant dif-
ferences were observed for the change in FEV1 or
exacerbations. Several serious adverse events occurred in
patients receiving active drug including cellulitis, pneumonia,
active tuberculosis, and sepsis (resulting in death); various
malignancies in the active treatment group terminated the
study prematurely.8 Despite some initially encouraging re-
sults, there remains no clear indications for the use of these
agents in asthma, and by inference, there is no clear role for
TNF in perpetuating asthma or asthma exacerbations.
CD4
CD4 T cells are likely to be involved as a source of
proinflammatory cytokines in asthma. Keliximab is a mono-
clonal antibody that causes a transient reduction in the num-
ber of CD4 T cells.9 A double blind, randomized, placebo-
controlled study with 22 severe oral corticosteroid dependent
asthmatics patients was completed. A subset of patients
received the highest dose of keliximab (3.0 mg/kg). There
was significant improvement of peak expiratory flow rates in
the high dose treatment arm. However, CD4 T cells re-
mained transiently reduced 14 days postinfusion, raising
safety concerns.10
CD23
CD23 is a low-affinity immunoglobulin E receptor
(FcRII) and is important in regulating IgE production.
IDEC-152 is a chimeric monoclonal antibody directed against
CD23. CD23 is expressed on T and B cells, neutrophils,
monocytes, and macrophages. CD23 is overexpressed in
allergic disease and may be involved in IgE overproduction,
which can lead to mast cell degranulation. A phase I dose-
escalating placebo-controlled study in 30 asthmatics demon-
strated that IDEC-152 caused a dose-dependent reduction in
serum IgE concentrations. No significant adverse events were
reported.11
CD25
Airway inflammation is associated with activated
CD25 T cells, IL-2, and soluble IL-2 receptors. Daclizumab
is a humanized monoclonal antibody directed against the
alpha subunit of the high affinity IL-2 receptor (CD25). This
inhibits IL-2 binding and release of inflammatory cytokines.
A randomized, double-blind, placebo-controlled, parallel-
group study was performed to evaluate the efficacy of dacli-
zumab in patients with moderate to severe asthma poorly
controlled on inhaled corticosteroids. There were 115 patients
enrolled in the study, 88 patients were randomized to the
treatment arm and 27 patients were randomized to the pla-
cebo arm. Treatment with daclizumab led to improvements in
FEV1, daytime asthma symptoms, and rescue 2 agonist use,
but the effects were modest. A similar frequency of adverse
advents was reported in the treatment and placebo groups.
However, 3 patients reported serious adverse events (anaphy-
laxis, varicella zoster virus meningitis and myelitis, and
breast cancer) in the treatment arm, likely related to the study
drug.12,13 One final consideration is that T-regulatory cells
also express CD25 and are believed to play a role in down-
regulating TH2 responses. Whether these cells are targeted in
a detrimental way in these studies is not known.
IgE
Immunoglobulin (Ig)E is an important mediator of
allergic reactions thought to be responsible for the induction
and maintenance of airway inflammation and related symp-
toms in many asthmatics. Omalizumab is a humanized mono-
clonal anti-IgE antibody that binds free circulating IgE and
prevents the interaction between IgE and high affinity (FcRI)
and low affinity (FcRII) IgE receptors on inflammatory cells.14
Omalizumab also down-regulates the surface expression of
FcRI on basophils, mast cells, and dendritic cells (Fig. 3).
Omalizumab was the first and only biologic agent approved by
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the Food and Drug Administration (FDA) for the treatment of
asthma and has been in use since June 2003.
The efficacy of omalizumab in the treatment of inhaled
corticosteroid–dependent asthma has been demonstrated in
numerous studies. Busse et al completed a phase III, double-
blind, placebo-controlled trial involving 525 subjects with
severe allergic asthma requiring daily inhaled corticosteroids.
The primary end point was the number of exacerbation
episodes during the steroid reduction period and the stable
steroid period. During the stable steroid phase, fewer omali-
zumab subjects than placebo subjects experienced one or
more exacerbations (14.6 vs. 23.3%; P  0.009). During the
steroid reduction phase, the omalizumab group had fewer
subjects with exacerbations (21.3 vs. 32.3%; P  0.04). The
median reduction in inhaled corticosteroid dose was signifi-
cantly greater in the omalizumab group than in the placebo
group (75 vs. 50%; P  0.001).15,16
The efficacy of omalizumab was demonstrated in other
clinical trials including INNOVATE. INNOVATE was a
double-blind, parallel-group study in which 419 subjects
were randomized to receive omalizumab or placebo for 28
weeks. The omalizumab group had a 26% reduction in the
rate of clinically significant exacerbations compared with
placebo (.68 vs. .91, P  0.042).17
A recent omalizumab observational study of 280 sub-
jects demonstrates similar findings. After 6 months, they
found a reduction in daily symptoms by 80%, nocturnal
symptoms by 86%, asthma exacerbations by 82%, hospital-
izations by 76%, unscheduled health care visits by 81%, and
improvement in quality of life (Mini Asthma Quality of Life
Questionnaire increased from 2.9 to 4.5 after 6 months of
treatment).14
Brown et al determined the incremental cost effective-
ness ratio of adding omalizumab to standard therapy (inhaled
corticosteroids and long-acting beta agonist). The base case
lifetime analysis of standard therapy versus standard therapy
plus omalizumab for the first 5 years, gave an incremental
cost effectiveness ratio of 31,209 Euros. This study suggests
that add-on omalizumab therapy is cost-effective in patients
with severe persistent allergic asthma.18
Regarding safety, the FDA recently issued an early
communication notice after receiving interim data from an
ongoing postmarketing surveillance study that showed a dis-
proportionate increase in heart problems potentially caused
by omalizumab side effects. EXCELS (Evaluating the Clin-
ical Effectiveness and Long-Term Safety in Patients with
Moderate to Severe Asthma) is an observational study to try
to determine long-term side effects of omalizumab. The FDA
reports that interim data from EXCELS show a dispropor-
tionate increase in ischemic heart disease, arrhythmias, car-
diomyopathy, and cardiac failure, pulmonary hypertension,
cerebrovascular disorders, and embolic, thrombotic, and
thrombophlebitic events in patients treated with omalizumab
compared with the control group. No causal relationship has
been identified and the FDA will provide additional informa-
tion as analyses become available.19 In addition, Limb et al
evaluated omalizumab and anaphylaxis events through post-
marketing surveillance from June 2003 through December
2006. An estimated 57,300 patients received omalizumab
during this period and 124 cases of anaphylaxis associated
with omalizumab administration were described. Many cases
had a delayed onset of anaphylaxis and a protracted progres-
sion of symptoms resulting in a black box warning.20
IL-4/IL-13
TH2 cytokines such as IL-4 and IL-13 may contribute to
airway inflammation. Pitrakinra is a recombinant human IL-4
variant that engages the IL-4R receptor complex to interfere
with binding of both IL-4 and IL-13. Wenzel et al evaluated
the effects of pitrakinra in atopic asthmatics in 2 randomized,
double blind placebo controlled phase II a studies. In the first
study, patients received either pitrakinra 25 mg subcutaneous
daily or placebo. There were fewer asthma related adverse
events (P  0.069) and lower beta agonist rescue use (P 
0.031). In the second study, patients received either pitrakinra
60 mg via nebulization twice daily or placebo followed by
inhaled allergen challenge. Patients in the treatment arm had
a remarkable reduction in the late phase response to allergen.
No serious adverse events were reported.21
AMG 317 is a monoclonal antibody that inhibits both
IL-4 and IL-13 by blocking the shared IL-4R chain. A
12-week randomized, double-blind, placebo-controlled phase
II study evaluated AMG 317 in moderate to severe asthmat-
ics. Patients were randomized to 12 weeks of weekly subcu-
taneous injections of AMG 317 or placebo. AMG 317 did not
demonstrate clinical efficacy across the overall group of
patients. Clinically significant improvements were observed
in several outcome measures in patients with higher baseline
Asthma Control Questionnaire scores. AMG 317 was safe
and well tolerated in this study.22
IL-5
One experimental monoclonal antibody against IL-5,
mepolizumab, has been studied in asthma and results have
FIGURE 3. Proposed mechanisms of action of omali-
zumab. Omalizumab decreases free IgE levels and reduces
FcRI receptor expression on mast cells and basophils. This
results in decreased mast cell activation and sensitivity, lead-
ing to a reduction in eosinophil influx and activation. Anti-
IgE treatment with omalizumab might result in decreased
mast cell survival. Omalizumab also reduces dendritic cell
FcRI receptor expression. Reprinted from reference 29, with
permission.
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been published. Initial studies in mild and moderate asthmat-
ics demonstrated significant reductions in blood and sputum
eosinophils; however, there were no significant changes in
any of the clinical endpoints measured including exacerbation
rates, FEV1, morning peak expiratory flow, rescue beta
agonist use, and quality of life.23
In a subsequent double-blind, placebo-controlled, par-
allel-group study, 61 subjects with refractory eosinophilic
asthma were randomized to receive mepolizumab or placebo
at monthly intervals, 29 subjects received mepolizumab and
32 received a placebo for 1 year. The mepolizumab group
experienced fewer severe exacerbations than placebo (2.0 vs.
3.4 exacerbations per subject; P 0.02) and greater improve-
ment on the Asthma Quality of Life Questionnaire (mean
increase from baseline .55 vs. .19, P 0.02). There were also
significant decreases in sputum and blood eosinophils in the
active treatment group. Improvements in eosinophil counts
after infusion of mepolizumab as compared with placebo
were reduced by a factor of 2.1 in bronchial biopsy specimens
(P  0.68), by a factor of 8.2 in bronchoalveolar lavage
specimens (P  0.06), and by a factor of 16.0 in bronchial
wash specimens (P  0.02). In addition, airway wall thick-
ness and total wall area measured by computed tomography
(CT) were reduced in the treatment arm group as compared
with placebo. There were no significant improvements in
symptoms, airway hyperresponsiveness, or FEV1 after bron-
chodilator use.24
A second smaller double-blind, placebo-controlled,
parallel-group study enrolled 20 asthmatic patients with per-
sistent sputum eosinophilia and symptoms despite prednisone
treatment. Nine patients were randomized to receive mepoli-
zumab (5 monthly infusions) and 11 patients to receive
placebo. During this period, 12 asthma exacerbations oc-
curred in 10 patients who received placebo (9 of the subjects
had sputum eosinophilia at the time of exacerbation). How-
ever, in the mepolizumab treatment group, only 1 patient had
an exacerbation. Patients in the treatment group were able to
use less prednisone than patients on placebo (84 vs. 48% of
maximum possible dose, P  0.04). There were also signif-
icant decreases in sputum and blood eosinophils in the active
treatment group. Improvements in asthma control and eosin-
ophil counts were maintained for 8 weeks after the last
infusion.25
The 2 most recent studies highlight the importance of
selecting the appropriate patient for this treatment. Mepoli-
zumab therapy may be especially useful in a subgroup of
asthmatics that have eosinophilic driven exacerbations that do
not respond to corticosteroid treatment. In retrospect, it now
seems likely that the initial IL-5 targeting studies may have
failed because of enrolling patients in whom their asthma was
not eosinophil driven. It remains to be determined whether IL-5
therapies can affect lung function and bronchial hyperreactivity
especially if used for longer periods of time.
Reslizumab is a humanized monoclonal antibody
against IL-5. Several clinical trials evaluating its safety and
efficacy are in progress. A phase II, multicenter randomized,
double-blind placebo-controlled trial in severe asthmatic
adult patients with persistent symptoms despite inhaled cor-
ticosteroids and elevated eosinophils in induced sputum is
underway. The primary end point of the study is improvement in
the Asthma Quality of Life Questionnaire. Secondary endpoints
include FEV1, asthma, exacerbations, and eosinophil values. No
data are available at the time of this publication.26
Several studies examining the effect of humanized
anti-IL-5R antibody (MEDI-563) are in progress. In vitro,
MEDI-563 mediated the lysis of IL-5R transfected cells
with a 200-fold higher potency in comparison to the parental
mAb. Reed et al studied the safety and biologic activity in 6
mild asthmatics after a single intravenous dose of MEDI-563.
Circulating eosinophils decreased below detection limits
within 24–48 hours of dosing. Because basophils also ex-
press IL-5R, this treatment may affect basophil numbers as
well. No serious adverse events were reported.27 Results of
additional completed clinical studies should be forthcoming
in the near future.30
IL-9
IL-9 increases airway inflammation, mucus production,
and mast cell differentiation, in large part by inducing other
TH2 cytokines. MEDI-528 is a novel human monoclonal
antibody against IL-9. Preclinical murine models demon-
strated inhibition of IL-9 caused reduced airway hyperrespon-
siveness and mast cell activation. A recent human phase I
study was completed and no serious adverse events were
reported.31 A phase IIa randomized, placebo-controlled, dou-
ble-blinded study is currently in progress.32
CONCLUSION
Examining the effects of biologic agents provides
unique and valuable insight into the pathobiology of asthma.
Furthermore, it is an ideal opportunity to identify mecha-
nisms inherent to severe refractory asthma. The development
of biologic agents has been a slow and arduous process;
however, a substantial amount of progress has been achieved.
Although omalizumab is an expensive medical treatment,
therapy may be cost effective in patients with uncontrolled
severe persistent allergic asthma because the majority of the
economic burden is in this population. Hopefully ongoing
efforts with biologicals will lead to improved management
options for our most severe asthma patients.
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